New EU trade rules could put poor countries in a billion dollar ‘green squeeze’ 
Adidas Unveils Innovative Triple-Red FC Bayern München Kit for 2024/25 Season 
Instacart, Uber Eats Forge Groundbreaking Partnership to Revolutionize Food Delivery 
Uganda’s tax system isn’t bringing in enough revenue but is targeting small business the answer? 
Can I take your order – and your data? 
BYD Shark Debuts in Mexico, Rivals Tesla Cybertruck and Ford F-150 Lightning 
Nigerians throw naira notes around to show love: but it could land you in jail 
Switch Successor Announcement Expected Before Next April, Nintendo States 
How to Protect Your Eyes at Work 
Impact investing in Paris suburban ‘banlieue’ neighbourhoods 
If using LinkedIn makes you feel like an imposter at work, here’s how to cope 
AstraZeneca Pulls Out Its COVID-19 Vaccine From Global Markets After Court Docs Shows Side Effects 
NFL, NBA, NASCAR Stars Resolve $2.4M Voyager Promo Lawsuit 
How India’s economy has fared under ten years of Narendra Modi 
Samsung Biologics signed a new deal with GSK, formerly GlaxoSmithKline. This will be their second manufacturing deal, and this time the agreement value is $296.1 million.
The amount is said to be almost 30% of the full-year revenue of Samsung last year, which was KRW1.5 trillion or around $1 billion, and the contract with GSK is in effect until the end of 2030. Samsung Biologics is currently the top Contract Manufacturing Organization in the world in terms of capacity, and its latest deal with the said British pharmaceutical industry company is for the supply of biopharma products.
Samsung Biologics and GSK plc confirmed their second collaborative contract late last week. As per The Korea Economic Daily, the biotech unit of the Samsung Group did not disclose the details of the exact products it will make for GSK under their contract.
One of their earlier deals was signed in May 2020, and it was a contract worth $231 million. It was also for the supply of biopharma products for eight years since the contract was made official. To be more specific, this was for the production and delivery of GSK’s Benlysta (belimumab) drug, which is used for the treatment of the autoimmune disease - lupus nephritis.
GSK and Samsung Biologics expanded their deal and signed another contract in August 2020, which was worth $368.1 million. It was a CMO agreement to produce sotrovimab, a SARS-CoV-2 monoclonal antibody that targets the COVID-19 virus.
In any case, the new deal is a remarkable expansion of the business relationship between Samsung Biologics and GSK. They already partnered in several projects, and now larger contracts are coming up
Meanwhile, Fierce Pharma reported that the new agreement comes as Samsung Biologics launches its “Super Plant,” which is also its fourth manufacturing facility. It sits in the company’s huge complex in Incheon, South Korea. It has invested more than $2 billion in the construction of this massive plant as part of its ambitious plan to become a major global player in the contract development and manufacturing organization scene.
